Aurinia Pharmaceuticals Inc.
AUPHNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $2.25B
- P/E (TTM)
- 7.17
- Forward P/E
- 3.76
- Dividend yield
- -
- 52-week range
- $11.48$19.25
- Volume (live)
- -
- Avg. volume (3M)
- 828.04K
Aurinia Pharmaceuticals (AUPH) Stock Price & Financial Analysis
Aurinia Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $16.81 - $17.31 |
|---|---|
| 52-Week High | $19.25 |
| 52-Week Low | $11.48 |
| Open | $17.27 |
| Volume (last close) | 649.22K |
| Average Volume (3M) | 828.04K |
| Revenue (TTM) | 311.51M |
|---|---|
| Net Income (TTM) | 314.11M |
| Free Cash Flow (TTM) | 173.97M |
| EPS (TTM) | $2.30 |
| Profit Margin | 100.84% |
| Operating Margin | 48.39% |
| Return on Equity (ROE) | 51.09% |
| Debt to Equity | 0.10 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 2.25B |
|---|---|
| Shares Outstanding | 133.53M |
| P/E Ratio (TTM) | 7.17 |
| Forward P/E | 3.76 |
| Price to Sales (P/S) | 7.23 |
| Price to Book (P/B) | 3.66 |
| EV/EBITDA | 11.82 |
| 50-Day MA | $16.26 |
|---|---|
| 200-Day MA | $15.58 |
| 1-Year Change | +49.65% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Aurinia Pharmaceuticals at a Glance
As of the Oct 23, 2026 close, Aurinia Pharmaceuticals (AUPH) has a market capitalization of $2.25B. The stock trades at 7.2× trailing earnings, 3.8× forward earnings and 7.2× sales. Over the trailing twelve months it earned $314.11M on revenue of $311.51M (a 100.8% profit margin) and generated $173.97M of free cash flow. Revenue grew 19.8% year over year.
As of its latest reported balance sheet, it holds $179.83M in cash and securities against $62.43M of debt, a net cash position of $117.40M.
Aurinia Pharmaceuticals does not currently pay a dividend.
The share price is up 49.7% over the past year. At $16.86 (the Oct 23, 2026 close) it sits within its 52-week range of $11.48 to $19.25, above its 200-day moving average of $15.58.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $18.00, 6.8% above the Oct 23, 2026 close.
Frequently Asked Questions About Aurinia Pharmaceuticals
What is the current stock price for AUPH?
As of the Oct 23, 2026 close, AUPH stock trades at $16.86. The 52-week range is $11.48–$19.25, with a day range of $16.81–$17.31.
What is the P/E ratio for AUPH?
As of the Oct 23, 2026 close, Aurinia Pharmaceuticals's trailing twelve-month (TTM) P/E ratio is 7.2, meaning investors pay $7.2 for every $1 of annual earnings. The forward P/E is 3.8, reflecting analyst expectations for future earnings. Aurinia Pharmaceuticals operates in the Healthcare sector.
Does AUPH pay dividends?
Aurinia Pharmaceuticals does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for AUPH?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for AUPH is Buy. The average 12-month price target is $18.00, a 6.8% upside from the Oct 23, 2026 close of $16.86.
What is the market cap of AUPH?
As of the Oct 23, 2026 close, Aurinia Pharmaceuticals's market capitalization is $2.25B, classifying it as a mid-cap company. Aurinia Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.